吉林長龍藥業(08049.HK)在過去3年不慎違反上市規則 未有公布認購理財產品協議
吉林長龍藥業(08049.HK)公布,在2018年1月17日至2020年12月29日期間,曾認購93份理財產品,但未有公布,不慎違反GEM上市規則。
公司指,就2019年及2020年的大部分違反情況而言,違反GEM上市規則乃由於公司管理層對銀保監會於2018年9月頒佈的該辦法有所誤解,而導致不慎違反。
公司在發現不合規情況後,已即時通知負責合規事宜的相關員工確保保本產品正確分類,並提醒相關員工向內部審核及監控部報告理財產品的認購/還款,以確保相關交易符合GEM上市規則的相關披露規定。負責投資理財產品及GEM上市規則合規事宜的相關員工現時已完全清楚有關分類及GEM上市規則的規定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.